NASDAQ$MNKD

MannKind Corp · Q4 2019 earnings

Q4 2019 earnings · · Investor relations

Briefing

MannKind reported Q4 2019 earnings, showing revenue growth driven by Afrezza sales and progress in collaborations.

MannKind Corporation's Q4 2019 total revenues reached $16.0 million, with Afrezza net revenue at $7.8 million, a 35% increase compared to Q4 2018. The company's net loss for the quarter was $14.3 million, or $0.07 per share. The collaboration with United Therapeutics on TreT continues to make progress.

  • Total revenue for Q4 2019 was $16.0 million.
  • Afrezza net revenue for Q4 2019 increased by 35% to $7.8 million compared to Q4 2018.
  • Collaborations and services revenue for Q4 2019 decreased by 20% to $8.2 million compared to Q4 2018.
  • Net loss for Q4 2019 was $14.3 million, or $0.07 per share.

Headline financials

Total Revenue

$16M

Previous: $16M-0.2%
EPS (adj)

-$0.07

Previous: -$0.06-16.7%
Net Income

-$14.3M

Previous: -$9.75M-46.7%
Operating Income

-$11.4M

Previous: -$7.73M-46.9%
Gross Profit

$3.13M

Previous: $9.96M-68.6%
Cash & Equivalents

$29.9M

Previous: $71.2M-58.0%
Total Assets

$93.7M

Previous: $108M-13.0%

Revenue & EPS history

MannKind · Revenue · Quarterly

$16M

Q4 2019-0.2%vs Q4 2018
Beat estimate in 9 of 16 quarters(56%)
ActualEstimate

Revenue by segment

MannKind · $16M total across 2 segments · Q4 2019

  • Collaborations and services
    $8.23M-20.5%
  • Afrezza
    $7.76M+35.4%

Forward guidance

MannKind is working with United Therapeutics on TreT and expects to file with the FDA within 12 months.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2019

Historical avgQ4 2019

-0.4%

Avg return

Earnings day

-0.7%

Avg return

5 days after

+1.5%

Avg return

30 days after

39%

25 / 64 earnings

Positive

+44.9%

Q3 2016

Best reaction

-28.5%

Q1 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+24.5%+17.5%+18.5%
Q4 2025-6.9%-16.3%-34.9%
Q3 2025+10.6%-1.1%+3.6%
Q1 2025-4.5%-2.7%-9.7%
Q4 2024-4.4%-5.9%-8.0%
Q3 2024-1.2%-4.8%-8.6%
Q2 2024-1.5%-1.5%+12.5%
Q1 2024-3.6%-1.3%+4.5%
Q4 2023+9.5%+25.7%+26.5%
Q3 2023-0.8%-6.8%-0.3%
Q2 2023+15.5%+11.2%-3.8%
Q1 2023+13.4%+9.0%+6.2%
Q4 2022+4.2%+1.7%-23.1%
Q3 2022+6.3%+20.7%+32.8%
Q2 2022-1.4%-4.6%-9.0%
Q1 2022-8.7%-8.7%+42.7%
Q4 2021-25.7%-24.9%-5.2%
Q3 2021-0.6%+3.1%-14.3%
Q2 2021+5.1%+5.4%+20.8%
Q1 2021-8.4%-3.9%-8.0%
Q4 2020-4.5%-36.8%-40.0%
Q3 2020+8.8%+19.0%+43.9%
Q2 2020+0.0%-4.2%-1.2%
Q1 2020-2.2%-0.7%+4.5%
Q4 2019-7.9%-16.4%-27.6%
Q3 2019-15.1%-16.8%-18.8%
Q2 2019-0.9%+4.6%+13.9%
Q1 2019-12.3%-19.4%-25.2%
Q4 2018+23.8%+17.2%+27.8%
Q3 2018+0.0%-1.1%-2.7%
Q2 2018-26.8%-29.3%-29.9%
Q1 2018+2.3%+8.7%+13.3%
Q4 2017-10.4%-13.5%-30.3%
Q3 2017-7.1%+0.3%-4.3%
Q2 2017-5.7%-2.5%+61.5%
Q1 2017+13.8%-5.4%+39.3%
Q4 2016+9.9%+2.5%-34.2%
Q3 2016+44.9%+51.2%+51.2%
Q2 2016-6.2%+2.0%-27.6%
Q1 2016-28.5%
Q4 2015+6.0%
Q3 2015-19.9%
Q2 2015+4.5%
Q1 2015-8.4%
Q4 2014+2.8%
Q3 2014-1.5%
Q2 2014-8.0%
Q1 2014+5.8%
Q4 2013+5.9%
Q3 2013+7.3%
Q2 2013-5.1%
Q1 2013+11.0%
Q4 2012-1.9%
Q3 2012+2.6%
Q2 2012+3.9%
Q1 2012-8.3%
Q4 2011+7.9%
Q3 2011-1.6%
Q2 2011-10.1%
Q1 2011-11.8%
Q4 2010-5.5%
Q3 2010-2.3%
Q2 2010-0.7%
Q1 2010+3.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro